Vanguard Capital Wealth Advisors Buys 50 Shares of Eli Lilly and Company (NYSE:LLY)

Vanguard Capital Wealth Advisors raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 10.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 545 shares of the company’s stock after acquiring an additional 50 shares during the quarter. Vanguard Capital Wealth Advisors’ holdings in Eli Lilly and Company were worth $318,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. International Assets Investment Management LLC lifted its position in Eli Lilly and Company by 61,268.8% during the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after acquiring an additional 7,330,815 shares during the period. Sapient Capital LLC acquired a new stake in Eli Lilly and Company during the 4th quarter worth $617,312,000. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in Eli Lilly and Company during the 3rd quarter worth $435,736,000. Vanguard Group Inc. boosted its stake in Eli Lilly and Company by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after purchasing an additional 659,838 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in Eli Lilly and Company by 24.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock worth $1,778,362,000 after purchasing an additional 645,473 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Citigroup upped their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. The Goldman Sachs Group upped their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday. Finally, Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $731.55.

Eli Lilly and Company Stock Up 6.0 %

NYSE:LLY traded up $44.36 on Tuesday, hitting $781.56. 7,432,651 shares of the company’s stock traded hands, compared to its average volume of 3,071,009. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 1 year low of $392.26 and a 1 year high of $800.78. The firm has a 50-day moving average price of $760.89 and a 200-day moving average price of $668.00. The company has a market cap of $742.61 billion, a PE ratio of 134.43, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.09 EPS. Equities analysts anticipate that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.